FIA
VRTX icon

Foundations Investment Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Foundations Investment Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$608K Buy
1,225
+61
+5% +$27K 0.01% 722
2026
Q1 		$520K Buy
1,164
+317
+37% +$148K 0.01% 712
2025
Q4 		$384K Sell
847
-17
-2% -$7.33K 0.01% 806
2025
Q3 		$338K Sell
864
-138
-14% -$57.7K ﹤0.01% 803
2025
Q2 		$446K Buy
1,002
+9
+0.9% +$4.15K 0.01% 622
2025
Q1 		$481K Buy
993
+149
+18% +$69.4K 0.01% 591
2024
Q4 		$340K Sell
844
-5
-0.6% -$2.32K 0.01% 630
2024
Q3 		$395K Buy
849
+86
+11% +$41.3K 0.01% 571
2024
Q2 		$358K Buy
763
+24
+3% +$10.4K 0.01% 572
2024
Q1 		$309K Sell
739
-3
-0.4% -$1.27K 0.01% 571
2023
Q4 		$322K Buy
+742
New +$274K 0.01% 532

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Foundations Investment Advisors's VRTX Position: Q2 2026 in Review

Foundations Investment Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 5.2% in Q2 2026, buying an estimated $27K and bringing the position to 1,225 shares worth $608K. The position accounts for 0.01% of the portfolio, ranked #722.

Foundations Investment Advisors first reported a position in VRTX in Q4 2023 and has held it in 11 quarters since. 1,749 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Foundations Investment Advisors held 1,225 shares of Vertex Pharmaceuticals worth $608K as of Q2 2026.
  • Foundations Investment Advisors bought 61 Vertex Pharmaceuticals shares in Q2 2026, an estimated $27K.
  • Vertex Pharmaceuticals made up 0.01% of Foundations Investment Advisors's portfolio in Q2 2026, its #722 holding.
  • Foundations Investment Advisors first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • 1,749 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Foundations Investment Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.